- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07271017
Biopsia Prostatica Robot-Assistita Con una Sonda Ecografica Innovativa
Biopsia prostatica robot-assistita con una nuova sonda ecografica
Prostate cancer (PCa) is the most diagnosed type of cancer and the second leading cause of cancer related deaths among US men, and its incidence has increased steadily in the last decade. Efforts to address the rise in PCa diagnosis without overdetection and overtreatment include targeted biopsy techniques for clinically significant PCa using magnetic resonance imaging (MRI), and precision targeted biopsy guided by ultrasound and fused to the MRI.
The study aims to improve prostate biopsy with a novel ultrasound probe and robot developed at Johns Hopkins, the ProBot device. The trial is a Phase 1 clinical trial to evaluate the safety and feasibility of the new device.
ProBot is an entirely new concept including a novel ultrasound probe and robot kinematics specifically designed for the prostate. It operates with only two degrees of freedom configured such that the motions for 3D image scanning and biopsy may not deform the prostate gland, thus improving the accuracy of MRI-ultrasound fusion and needle targeting at biopsy.
ProBot is a small and lightweight robot (1.3Kg including the ultrasound probe). It allows hands-free operation of its ultrasound probe at 3D image scanning and needle targeting supervised by the urologist.
In addition to MRI-targeted biopsy (TB), at systematic biopsy (SB), instead of using the common template plan that is the same for all patients, the innovative software optimizes the plan for each patient to obtain a diagnosis that is representative of the whole gland histology. The ProBot robot is also uniquely capable of transrectal (TR) and transperineal (TP) biopsy.
The aims of the study are to determine the safety and feasibility of the new device at TR and TP biopsies.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Rana Harb
- Numero di telefono: 410-502-5500
- Email: rharb1@jhmi.edu
Backup dei contatti dello studio
- Nome: Sara A Naizghi
- Numero di telefono: 720-965-9494 4105501980
- Email: snaizgh1@jh.edu
Luoghi di studio
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Reclutamento
- Johns Hopkins Hospital
-
Contatto:
- Rana Harb
- Numero di telefono: 410-502-5500
- Email: rharb1@jhmi.edu
-
Contatto:
- Sara A Naizghi
- Numero di telefono: 720-965-9494
- Email: snaizgh1@jh.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Included in the study will be:
-
Men between the ages of 40 and 75
-
Men must have one of the following "high risk" features:
- PSA > 4.0 ng/ml and/or abnormal digital rectal examination (DRE)
- ASAP (atypical small acinar proliferation) on previous biopsy
-
Men with mpMRI or bpMRI exams, including both PI-RADS ≤2 and PI-RADS ≥3.
Excluded from the study will be patients without available mpMRI exams and patients:
-
Females and children because of the prostate cancer targeted disease.
-
Patients who are not recommended or in whom TR or TP prostate biopsy is considered high-risk:
- Patients with previous rectal surgery.
- Patients with anal stenosis or coagulopathy.
- Patients on active anticoagulation medication (eg. Coumadin, Lovenox, or Heparin).
- Patients who cannot tolerate periprostatic Lidocaine block anesthesia or in whom anesthesia is considered high-risk.
-
Patients who already had a prostate biopsy taken with the ProBot investigational device.
-
Vulnerable populations, such as prisoners, institutionalized individuals.
-
Patients who are unwilling or unable to sign informed consent (no assent required).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Fattibilità del dispositivo
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Transrectal biopsy (TR)
Biopsy guided by transrectal ultrasound fused with MRI and needle inserted on a transrectal path |
Precision personalized prostate biopsy with a novel ultrasound probe and robot, ProBot |
|
Sperimentale: Transperineal biopsy (TP)
Biopsy guided by transrectal ultrasound fused with MRI and needle inserted on a transperineal path. |
Precision personalized prostate biopsy with a novel ultrasound probe and robot, ProBot |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Device feasibility as assessed by patient discomfort score
Lasso di tempo: Immediately after the procedure
|
Scale 1-10, 10 highest discomfort |
Immediately after the procedure
|
|
Device feasibility as assessed by maximal procedural pain
Lasso di tempo: Immediately after the procedure
|
Scale 1-10, 10 highest pain |
Immediately after the procedure
|
|
Device feasibility as assessed by the rate of complications
Lasso di tempo: Throughout the study, each case recorded within 1 month of the procedure
|
Rate of complications |
Throughout the study, each case recorded within 1 month of the procedure
|
|
Device feasibility as assessed by serious adverse events
Lasso di tempo: Up to 1 month post procedure
|
Serious Adverse events throughout the study |
Up to 1 month post procedure
|
|
Device feasibility as assessed by the rate of successful completion of cases
Lasso di tempo: Immediately post procedure
|
Rate of cases completed successfully throughout the study |
Immediately post procedure
|
|
Device feasibility as assessed by the procedure time
Lasso di tempo: Immediately post procedure
|
Times of the procedures measured in minutes throughout the study |
Immediately post procedure
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Prostate cancer detection rates at targeted biopsy (TB)
Lasso di tempo: Up to 1 month post procedure
|
Clinically significant PCa detection rates at TB throughout the study |
Up to 1 month post procedure
|
|
Prostate cancer detection rates at systematic biopsy (SB)
Lasso di tempo: Up to one month post procedure
|
Clinically significant PCa detection rates at SB throughout the study |
Up to one month post procedure
|
|
Needle targeting errors
Lasso di tempo: Immediately post procedure
|
Measured in ultrasound throughout the study |
Immediately post procedure
|
|
Prostate deformations (mm)
Lasso di tempo: Immediately post procedure
|
Maximum deformation of the gland between the start and end of the procedure measured in [mm] throughout the study |
Immediately post procedure
|
|
Prostate displacement (mm)
Lasso di tempo: Immediately post procedure
|
Displacement of the gland between the start and end of the procedure measured in [mm] throughout the study |
Immediately post procedure
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Misop Han, MD, Johns Hopkins University
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- IRB00229568
- R01CA303859 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .